Remission for at least 24 weeks · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
Mepolizumab may leads to higher remission for at least 24 weeks compared with placebo (low certainty).
1 finding from 1 review
RR 9.5 [2.3, 39.21]
Studies not reported
Low
Flare‐ups or relapse (continuous) · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any adverse event · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe AEs · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis
It is very uncertain whether infliximab changes any severe AEs compared with rituximab (very low certainty).
1 finding from 1 review
RR 1.78 [0.2, 16.1]
Studies not reported
Very low
Withdrawals due to adverse events · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis
It is very uncertain whether infliximab changes any withdrawals due to AEs compared with rituximab (very low certainty).
1 finding from 1 review
RR 2.7 [0.13, 58.24]
Studies not reported
Very low
Durable remission · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
Mepolizumab may leads to higher durable remission within the first 24 weeks sustained until week 52 compared with placebo (low certainty).
1 finding from 1 review
RR 13 [1.75, 96.33]
Studies not reported
Low
Relapse · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
Mepolizumab probably leads to lower disease relapse compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.68 [0.53, 0.86]
Studies not reported
Moderate
Disease flare · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any adverse event · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
Mepolizumab showed no clear difference in any adverse event compared with placebo (low certainty).
1 finding from 1 review
RR 1.03 [0.96, 1.11]
Studies not reported
Low
Any serious adverse event · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
Mepolizumab showed no clear difference in any serious adverse event compared with placebo (low certainty).
1 finding from 1 review
RR 0.67 [0.35, 1.28]
Studies not reported
Low
Withdrawals due to adverse events · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
Mepolizumab showed no clear difference in any withdrawals due to AEs compared with placebo (low certainty).
1 finding from 1 review
RR 2 [0.19, 21.54]
Studies not reported
Low
MortalityNumber of participants: 285(2 RCTs) WGET 2005 · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in mortalityNumber of participants: 285(2 RCTs) WGET 2005 compared with standard therapy with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Treatment failure day‐28 PCR‐adjusted(PP population) · children aged 14 years or younger with uncomplicated P falciparum malaria
The intervention showed no clear difference in treatment failure day‐28 PCR‐adjusted(PP population) (low certainty).
1 finding from 1 review
Intervention not reported
Treatment failureday‐28 PCR‐adjusted(ITT population) · children aged 14 years or younger with uncomplicated P falciparum malaria
The intervention showed no clear difference in treatment failureday‐28 PCR‐adjusted(ITT population) (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · children aged 14 years or younger with uncomplicated P falciparum malaria
The intervention showed no clear difference in serious adverse events (low certainty).
1 finding from 1 review
Intervention not reported
Drug‐related adverse events · children aged 14 years or younger with uncomplicated P falciparum malaria
The intervention probably leads to lower drug‐related adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Drug‐related vomiting · children aged 14 years or younger with uncomplicated P falciparum malaria
The intervention showed no clear difference in drug‐related vomiting (low certainty).
1 finding from 1 review
Intervention not reported
Acceptability · children aged 14 years or younger with uncomplicated P falciparum malaria
1 finding from 1 review
Disease‐specific quality of life · children with obstructive sleep‐disordered breathing
1 finding from 1 review
Peri‐operative blood loss (Volume measured in mL) · children with obstructive sleep‐disordered breathing
1 finding from 1 review